The role of COX-2 inhibition in breast cancer treatment and prevention

Seminars in Oncology

Volumn 31, Issue SUPPL. 7, 2004, Pages 22-29

  Arun, Banu ^b   Goss, Paul ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; CELECOXIB; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; LETROZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; TAMOXIFEN; TRASTUZUMAB; VOROZOLE;

ABDOMINAL PAIN; ANGIOGENESIS; BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CLINICAL TRIAL; ENZYME INDUCTION; ENZYME INHIBITION; HEADACHE; HOT FLUSH; HUMAN; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SWEATING; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANTICARCINOGENIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CLINICAL TRIALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES;

EID: 3042748128     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seminoncol.2004.03.042     Document Type: Review

References (31)

1. Schreimenemachers D., Everson R. Aspirin use and lung, colon, breast cancer incidence in a prospective study. Epidemiology. 5:1994;138-146
2. Rolland P.H., Martin P.M., Jacquemier J., et al. Prostaglandin in human breast cancer Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst. 64:1980;1061-1070
3. Bennett A., Charlier E.M., McDonald A.M., et al. Prostaglandin and breast cancer. Lancet. 2:1977;624-626
4. Parrett M.L., Harris R.E., Joarder F.S., et al. Cyclooxygenase-2 expression in human breast cancer. Int J Oncol. 10:1997;503-507
5. Hwang D., Scollard D., Bryne J., et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 90:1998;455-460
6. Ristimaki A., Sivula A., Lundin J., et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 62:2002;632-635
7. Half E., Tang X.M., Gwyn K., et al. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinomas in situ. Cancer Res. 62:2002;1676-1681
8. Subbaramaiah K., Norton L., Gerald W., et al. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. Evidence for involvement of AP-1 and PEA3. J Biol Chem. 277:2002;18649-18657
9. Liu C.H., Chang S.H., Narko K., et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 276:2001;18563-18569
10. Dannenberg A.J., Howe L.R. The role of COX-2 in breast and cervical cancer. Prog Exp Tumor Res. 37:2003;90-106
11. Sheng H., Shao J., Morrow J.D., et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 58:1998;362-366
12. Sonoshita M., Takaku K., Sasaki N., et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc (Delta 716) knockout mice. Nat Med. 9:2001;1048-1051
13. 2 via cyclic AMP, leading to promoter II of the CYP19 (aromatase) gene. Endocrinology. 137:1996;5739-5742
14. Brueggemeier R.W., Richards J.A., Joomprabutra S., et al. Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents. J Steroid Biochem Mol Biol. 79:2001;75-84
15. Brueggemeier R.W., Quinn A.L., Parrett M.L., et al. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett. 140:1999;27-35
16. Brodie A.M., Lu Q., Long B.J., et al. Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol. 79:2001;41-47
17. Khuder S.A., Mutgi A.B. Breast cancer and NSAID use A meta-analysis. Br J Cancer. 84:2001;1188-1192
18. Harris R.E., Chlebowski R.T., Jackson R.D., et al. Inverse association of breast cancer and NSAIDs Results from the Women's Health Initiative (WHI). Proc Am Assoc Cancer Res. 44:2003;4893. (abstr)
19. Harris R.E., Alshafie G.A., Abou-Issa H., et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor. Cancer Res. 60:2000;2101-2103
20. Alshafie G.A., Abou-Issa H.M., Seibert K., et al. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep. 7:2000;1377-1381
21. Abou-Issa H.M., Alshafie G.A., Seibert K., et al. Dose-dependent effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res. 21:2001;3425-3432
22. Nakatsugi S., Ohta T., Kawamori T., et al. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazol [4, 5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res. 91:2000;886-892
23. Howe L.R., Subbaramaiah K., Patel J., et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res. 62:2002;5405-5407
24. Arun B., Zhang H., Mirza N.Q., et al. Growth inhibition of breast cancer cells by celecoxib. Breast Cancer Res Treat. 69:2001;234. (abstr)
25. Dang C.T., Dickler M.N., Moasser M.M., et al. Celecoxib (C) and trastuzumab (Herceptin) (H) is feasible after H for HER-2/neu overexpressing (H2+) metastatic breast cancer (MBC) patients (pts). Proc Am Soc Clin Oncol. 21:2002;48b. (abstr 2003)
26. Canney P.A. A phase II study of the efficacy and tolerability of the combination of exemestane with the cyclooxygenase-2 inhibitor celecoxib in postmenopausal women with advanced breast cancer. Proc Am Soc Clin Oncol. 22:2000;40. (abstr)
27. Goss P.E., Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol. 19:2001;881-894
28. Mokbel K., Kirkpatrick K.L. Recent advances in breast cancer (the Twenty-fourth San Antonio Breast Cancer Symposium, December, 2001). Curr Med Res Opin. 18:2002;26-29
29. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 349:2003;1793-1802
30. Chow L.W.C., Toi M. Prospective pilot study of the preoperative use of celecoxib (CELEBREX) and FEC for the treatment of locally advanced breast cancer. Breast Cancer Res Treat. 76:(suppl 1):2002;S54. (abstr)
31. Toi M., Chow L.W. Celecoxib anti-aromatase neoadjuvant (CAAN) therapy for locally advanced breast cancer Preliminary results of a prospective randomized trial. Proc Am Soc Clin Oncol. 22:2003;83. (abstr)